Virax Biolabs Group Limited(VRAX)

Biotechnology · Lanarkshire, SC

$2.03-0.37 (-15.42%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T21:03:58.336Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:03:58.336Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-03-31: N/A
Quote market capitalization: 378,849
Total debt · period ending 2026-03-31: 414,387
Cash · period ending 2026-03-31: 6,438,909

FMP input reference: 76ce780248c1f493ccbdb0751af92273333f1ee075484263629f1dd5eb2dbf7e

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

VRAX EBITDA Yield Metrics

EBITDA YIELD

N/A

VRAX Competitors' EBITDA Yield

VRAX

Virax Biolabs Group Limited

Current

Market Cap

$378849.00

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NIKI

Niki BioSolutions, Inc.

vs VRAX

Market Cap

$403887.00

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XRTX

XORTX Therapeutics Inc.

vs VRAX

Market Cap

$481786.00

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SPRC

SciSparc Ltd.

vs VRAX

Market Cap

$250443.00

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VIVS

VivoSim Labs, Inc.

vs VRAX

Market Cap

$518606.00

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HCWB

HCW Biologics Inc.

vs VRAX

Market Cap

$545796.00

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SLXN

Silexion Therapeutics Ltd.

vs VRAX

Market Cap

$110112.00

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PBM

Psyence Biomedical Ltd.

vs VRAX

Market Cap

$95475.00

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SXTC

China SXT Pharmaceuticals, Inc.

vs VRAX

Market Cap

$667469.00

EBITDA Yield

N/A

TTM Avg

0.00%

3Y Avg

0.00%

5Y Avg

0.00%

PRFX

PRF Technologies Ltd.

vs VRAX

Market Cap

$70884.00

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Virax Biolabs Group Limited (VRAX)	$378849.00	N/A	N/A	N/A	N/A
Niki BioSolutions, Inc. (NIKI)vs ›	$403887.00	N/A	N/A	N/A	N/A
XORTX Therapeutics Inc. (XRTX)vs ›	$481786.00	N/A	N/A	N/A	N/A
SciSparc Ltd. (SPRC)vs ›	$250443.00	N/A	N/A	N/A	N/A
VivoSim Labs, Inc. (VIVS)vs ›	$518606.00	N/A	N/A	N/A	N/A
HCW Biologics Inc. (HCWB)vs ›	$545796.00	N/A	N/A	N/A	N/A
Silexion Therapeutics Ltd. (SLXN)vs ›	$110112.00	N/A	N/A	N/A	N/A
Psyence Biomedical Ltd. (PBM)vs ›	$95475.00	N/A	N/A	N/A	N/A
China SXT Pharmaceuticals, Inc. (SXTC)vs ›	$667469.00	N/A	0.00%	0.00%	0.00%
PRF Technologies Ltd. (PRFX)vs ›	$70884.00	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

VRAX EBITDA Yield Metrics

VRAX Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics